The FDA has approved datopotamab deruxtecan-dlnk (Datroway; Dato-DXd) as a first-line option for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The decision is based on phase 3 TROPION-Breast02 results comparing Dato-DXd with investigator’s-choice chemotherapy.